

# Michael Christoph FrÃ¼hwald

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6337251/publications.pdf>

Version: 2024-02-01

79  
papers

7,207  
citations

147801

31  
h-index

74163

75  
g-index

81  
all docs

81  
docs citations

81  
times ranked

9593  
citing authors

#	ARTICLE	IF	CITATIONS
1	Age, American Thyroid Association Risk Group, and Response to Therapy Are Prognostic Factors in Children With Differentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e165-e177.	3.6	17
2	Current and Emerging Therapeutic Approaches for Extracranial Malignant Rhabdoid Tumors. <i>Cancer Management and Research</i> , 2022, Volume 14, 479-498.	1.9	11
3	Exploring the Mechanisms Underlying the Effectiveness of Psychosocial Aftercare in Pediatric Chronic Pain Treatment: A Qualitative Approach. <i>Children</i> , 2022, 9, 407.	1.5	1
4	Infants and Newborns with Atypical Teratoid Rhabdoid Tumors (ATRT) and Extracranial Malignant Rhabdoid Tumors (eMRT) in the EU-RHAB Registry: A Unique and Challenging Population. <i>Cancers</i> , 2022, 14, 2185.	3.7	9
5	ATRT-12. LIN28A expression correlates with poor prognosis and the MYC subgroup in AT/RTs. <i>Neuro-Oncology</i> , 2022, 24, i5-i5.	1.2	0
6	HGG-49. Gliomatosis cerebri in children: A collaborative report from the European Society for Pediatric Oncology (SIOPE). <i>Neuro-Oncology</i> , 2022, 24, i72-i73.	1.2	0
7	Clinical and genetic risk factors define two risk groups of extracranial malignant rhabdoid tumours (eMRT/RTK). <i>European Journal of Cancer</i> , 2021, 142, 112-122.	2.8	15
8	Current recommendations for clinical surveillance and genetic testing in rhabdoid tumor predisposition: a report from the SIOPE Host Genome Working Group. <i>Familial Cancer</i> , 2021, 20, 305-316.	1.9	20
9	Clinical and molecular characterization of patients with stage 4(M) neuroblastoma aged less than 18 months without MYCN amplification. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29038.	1.5	4
10	Evidence for a low-penetrant extended phenotype of rhabdoid tumor predisposition syndrome type 1 from a kindred with gain of <i>SMARCB1</i> exon 6. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29185.	1.5	0
11	A Retrospective 5-Year Single Center Study Highlighting the Risk of Cancer Predisposition in Adolescents and Young Adults. <i>Cancers</i> , 2021, 13, 3033.	3.7	1
12	Clinical evidence for a biological effect of epigenetically active decitabine in relapsed or progressive rhabdoid tumors. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29267.	1.5	7
13	Effectiveness of a Psychosocial Aftercare Program for Youth Aged 8 to 17 Years With Severe Chronic Pain. <i>JAMA Network Open</i> , 2021, 4, e2127024.	5.9	5
14	Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study. <i>Neuro-Oncology</i> , 2021, 23, 1012-1023.	1.2	19
15	Spinal cord atypical teratoid/rhabdoid tumors in children: Clinical, genetic, and outcome characteristics in a representative European cohort. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28022.	1.5	12
16	Sickle cell disease in Germany: Results from a national registry. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28130.	1.5	20
17	Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors. <i>Neuro-Oncology</i> , 2020, 22, 1006-1017.	1.2	72
18	Macrophage-tumor cell interaction promotes ATRT progression and chemoresistance. <i>Acta Neuropathologica</i> , 2020, 139, 913-936.	7.7	24

#	ARTICLE	IF	CITATIONS
19	Molecular subgrouping of atypical teratoid/rhabdoid tumors—a reinvestigation and current consensus. <i>Neuro-Oncology</i> , 2020, 22, 613-624.	1.2	133
20	Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedure. <i>BMC Pharmacology &amp; Toxicology</i> , 2020, 21, 37.	2.4	7
21	Advancing biology-based therapeutic approaches for atypical teratoid rhabdoid tumors. <i>Neuro-Oncology</i> , 2020, 22, 944-954.	1.2	25
22	Revisiting the genotype–phenotype correlation in children with medullary thyroid carcinoma: A report from the GPOH–MET registry. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28171.	1.5	6
23	Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. <i>Nature Medicine</i> , 2020, 26, 712-719.	30.7	172
24	Local Stage Dependent Necessity of Radiation Therapy in Rhabdoid Tumors of the Kidney (RTK). <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 667-675.	0.8	6
25	Novel Two MRT Cell Lines Established from Multiple Sites of a Synchronous MRT Patient. <i>Anticancer Research</i> , 2020, 40, 6159-6170.	1.1	0
26	How I approach hereditary cancer predisposition in a child with cancer. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27916.	1.5	7
27	Identification and Analyses of Extra-Cranial and Cranial Rhabdoid Tumor Molecular Subgroups Reveal Tumors with Cytotoxic T Cell Infiltration. <i>Cell Reports</i> , 2019, 29, 2338-2354.e7.	6.4	74
28	Next-generation reference intervals for pediatric hematology. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1595-1607.	2.3	42
29	Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience. <i>European Journal of Cancer</i> , 2019, 114, 27-35.	2.8	51
30	Two molecularly distinct atypical teratoid/rhabdoid tumors (or tumor components) occurring in an infant with rhabdoid tumor predisposition syndrome 1. <i>Acta Neuropathologica</i> , 2019, 137, 847-850.	7.7	7
31	Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia. <i>Clinical Epigenetics</i> , 2019, 11, 188.	4.1	27
32	Comprehensive Analysis of Chromatin States in Atypical Teratoid/Rhabdoid Tumor Identifies Diverging Roles for SWI/SNF and Polycomb in Gene Regulation. <i>Cancer Cell</i> , 2019, 35, 95-110.e8.	16.8	65
33	High-dose treatment for malignant rhabdoid tumor of the kidney: No evidence for improved survival—the Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH) experience. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26746.	1.5	35
34	The landscape of genomic alterations across childhood cancers. <i>Nature</i> , 2018, 555, 321-327.	27.8	1,068
35	The extraordinary challenge of treating patients with congenital rhabdoid tumors—a collaborative European effort. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26999.	1.5	15
36	Germline variants in SMARCB1 and other members of the BAF chromatin-remodeling complex across human disease entities: a meta-analysis. <i>European Journal of Human Genetics</i> , 2018, 26, 1083-1093.	2.8	30

#	ARTICLE	IF	CITATIONS
37	DNA methylation-based classification of central nervous system tumours. <i>Nature</i> , 2018, 555, 469-474.	27.8	1,872
38	Emerging therapeutic targets for the treatment of malignant rhabdoid tumors. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 365-379.	3.4	46
39	Limbic encephalitis with LGI1 antibodies in a 14-year-old boy. <i>European Journal of Paediatric Neurology</i> , 2018, 22, 190-193.	1.6	22
40	ATRT-15. SPINAL CORD ATYPICAL TERATOID/RHABDOID TUMORS (AT/RT) IN CHILDREN: RESULTS OF A EUROPEAN RETROSPECTIVE ANALYSIS UNDER THE AUSPICES OF THE EU-RHAB STUDY GROUP. <i>Neuro-Oncology</i> , 2018, 20, i30-i30.	1.2	0
41	Liver transplantation as a potentially lifesaving measure in neuroblastoma stage 4S. <i>Pediatric Hematology and Oncology</i> , 2017, 34, 17-23.	0.8	7
42	Pediatric NUT-midline carcinoma: Therapeutic success employing a sarcoma based multimodal approach. <i>Pediatric Hematology and Oncology</i> , 2017, 34, 231-237.	0.8	47
43	Cribriform neuroepithelial tumor: molecular characterization of a SMARCB1-deficient non-rhabdoid tumor with favorable long-term outcome. <i>Brain Pathology</i> , 2017, 27, 411-418.	4.1	58
44	BRD9 Inhibition, Alone or in Combination with Cytostatic Compounds as a Therapeutic Approach in Rhabdoid Tumors. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1537.	4.1	42
45	Immunotherapy in atypical teratoid-rhabdoid tumors: Data from a survey of the HGG-Immuno Group. <i>Cytotherapy</i> , 2016, 18, 1178-1186.	0.7	18
46	Next-generation personalised medicine for high-risk paediatric cancer patients – The INFORM pilot study. <i>European Journal of Cancer</i> , 2016, 65, 91-101.	2.8	262
47	Improved 6-year overall survival in AT/RT – results of the registry study Rhabdoid 2007. <i>Cancer Medicine</i> , 2016, 5, 1765-1775.	2.8	73
48	Rapid Diagnosis of an AT/RT by the Detection of a Heterozygous SMARCB1 Germ Line Deletion in an Infant. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1451-1453.	1.5	1
49	Atypical teratoid/rhabdoid tumors – current concepts, advances in biology, and potential future therapies. <i>Neuro-Oncology</i> , 2016, 18, 764-778.	1.2	185
50	Long-term survival of an infant with an atypical teratoid/rhabdoid tumor following subtotal resection and low-cumulative dose chemotherapy: a case report. <i>Child's Nervous System</i> , 2016, 32, 1157-1161.	1.1	3
51	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. <i>Cancer Cell</i> , 2016, 29, 379-393.	16.8	438
52	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. <i>Cell</i> , 2016, 164, 1060-1072.	28.9	702
53	Strategies to improve the quality of survival for childhood brain tumour survivors. <i>European Journal of Paediatric Neurology</i> , 2015, 19, 619-639.	1.6	36
54	Feasibility of Intensive Multimodal Therapy in Infants Affected by Rhabdoid Tumors – Experience of the EU-RHAB registry. <i>Klinische Padiatrie</i> , 2014, 226, 143-148.	0.6	33

#	ARTICLE	IF	CITATIONS
55	Arsenic trioxide inhibits tumor cell growth in malignant rhabdoid tumors <i>in vitro</i> and <i>in vivo</i> by targeting overexpressed Gli1. <i>International Journal of Cancer</i> , 2014, 135, 989-995.	5.1	42
56	Favorable outcome of patients affected by rhabdoid tumors due to rhabdoid tumor predisposition syndrome (RTPS). <i>Pediatric Blood and Cancer</i> , 2014, 61, 919-921.	1.5	41
57	Synchronous congenital malignant rhabdoid tumor of the orbit and atypical teratoid/rhabdoid tumor—feasibility and efficacy of multimodal therapy in a long-term survivor. <i>Cancer Genetics</i> , 2014, 207, 429-433.	0.4	28
58	Malignant rhabdoid tumor of the kidney: significantly improved response to pre-operative treatment intensified with doxorubicin. <i>Cancer Genetics</i> , 2014, 207, 434-436.	0.4	14
59	Epigenetic repression of the dopamine receptor D4 in pediatric tumors of the central nervous system. <i>Journal of Neuro-Oncology</i> , 2014, 116, 237-249.	2.9	13
60	High-dose chemotherapy (HDCT) with auto-SCT in children with atypical teratoid/rhabdoid tumors (AT/RT): a report from the European Rhabdoid Registry (EU-RHAB). <i>Bone Marrow Transplantation</i> , 2014, 49, 370-375.	2.4	58
61	SMARCA4-mutated atypical teratoid/rhabdoid tumors are associated with inherited germline alterations and poor prognosis. <i>Acta Neuropathologica</i> , 2014, 128, 453-456.	7.7	155
62	Clinical and genetic features of rhabdoid tumors of the heart registered with the European Rhabdoid Registry (EU-RHAB). <i>Cancer Genetics</i> , 2014, 207, 379-383.	0.4	6
63	Rhabdoid Tumors: Clinical Approaches and Molecular Targets for Innovative Therapy. <i>Pediatric Hematology and Oncology</i> , 2013, 30, 587-604.	0.8	30
64	Bone Involvement in Atypical Teratoid/Rhabdoid Tumors of the CNS. <i>American Journal of Neuroradiology</i> , 2013, 34, 2039-2042.	2.4	24
65	High-resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumors. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 185-190.	2.8	138
66	Somatostatin receptor subtype 2 (sst2) is a potential prognostic marker and a therapeutic target in medulloblastoma. <i>Child's Nervous System</i> , 2013, 29, 1253-1262.	1.1	12
67	Nutritional status of children and young adults with Ewing Sarcoma or osteosarcoma at diagnosis and during multimodality therapy. <i>Pediatric Blood and Cancer</i> , 2013, 60, 166-166.	1.5	5
68	Infantile Fibrosarcoma—An Important Differential Diagnosis of Congenital Vascular Tumors. <i>Pediatric Hematology and Oncology</i> , 2012, 29, 545-548.	0.8	19
69	Sensitivity of fine-needle biopsy in detecting pediatric differentiated thyroid carcinoma. <i>Pediatric Blood and Cancer</i> , 2012, 59, 233-237.	1.5	16
70	Tumors of the Central Nervous System in Children and Adolescents. <i>Deutsches Arzteblatt International</i> , 2011, 108, 390-7.	0.9	27
71	Claudin6 is of Limited Sensitivity and Specificity for the Diagnosis of Atypical Teratoid/Rhabdoid Tumors. <i>Brain Pathology</i> , 2011, 21, 558-563.	4.1	14
72	Frequency, Risk Factors and Survival of Children With Atypical Teratoid Rhabdoid Tumors (AT/RT) of the CNS Diagnosed between 1988 and 2004, and Registered to the German HIT Database. <i>Pediatric Blood and Cancer</i> , 2011, 57, 978-985.	1.5	121

#	ARTICLE	IF	CITATIONS
73	Germline Nonsense Mutation and Somatic Inactivation of SMARCA4/BRG1 in a Family with Rhabdoid Tumor Predisposition Syndrome. <i>American Journal of Human Genetics</i> , 2010, 86, 279-284.	6.2	288
74	Clinical and molecular features in patients with atypical teratoid rhabdoid tumor or malignant rhabdoid tumor. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 176-181.	2.8	96
75	The Epigenetics of Cancer in Children. <i>Klinische Padiatrie</i> , 2008, 220, 333-341.	0.6	17
76	Rhabdoid tumors in children: prognostic factors in 70 patients diagnosed in Germany. <i>Oncology Reports</i> , 2008, 19, 819-23.	2.6	65
77	Non-linkage of familial rhabdoid tumors to SMARCB1 implies a second locus for the rhabdoid tumor predisposition syndrome. <i>Pediatric Blood and Cancer</i> , 2006, 47, 273-278.	1.5	65
78	Somatostatin Receptor Subtype 2 Is Expressed by Supratentorial Primitive Neuroectodermal Tumors of Childhood and Can Be Targeted for Somatostatin Receptor Imaging. <i>Clinical Cancer Research</i> , 2004, 10, 2997-3006.	7.0	27
79	DNA Methylation Patterns in Cancer. <i>Molecular Diagnosis and Therapy</i> , 2003, 3, 245-260.	3.3	17